Aeon Biopharma announces rescheduling of BPD Type 2a meeting with FDA

AEON Biopharma (AEON) announced the first closing of its previously announced private placement. Additionally, the Company announced that the U.S. Food and Drug Administration has proposed a new date of January 21, 2026 for AEON’s Biosimilar Biological product Development Type 2a meeting. The meeting had previously been scheduled for November 19. The first closing of the PIPE occurred on November 18 and resulted in $1.79M in proceeds to AEON. The second closing of the PIPE will be subject to stockholder approval and the satisfaction of the other closing conditions required under the securities purchase agreement entered for the transaction. The first closing proceeds, along with the anticipated proceeds from the second closing, will enable uninterrupted execution of AEON’s analytical program and are expected to accelerate ABP-450’s biosimilar development by up to six months. Separately, on November 18, the FDA informed AEON that the BPD Type 2a meeting would be rescheduled and proposed January 21, 2026 as the new meeting date. The Type 2a meeting will review AEON’s analytical development plan and initial data supporting biosimilarity. The FDA did not cite any scientific or program-related issues in connection with the scheduling change and promptly provided the Company with the new proposed date, underscoring continued engagement with AEON’s biosimilar program.